The human prostate is subject to invasion by gramnegative facultative bacilli, enterococci, Neisseria gonorrhoeae, and Chlamydia and Mycoplasma organisms. The resulting nidus may either infect prostatic tissue directly or serve as a source for recurrent infection of the urinary tract. Successful treatment of prostatic infection is hampered by poor penetration of most available antimicrobial agents into prostatic secretions and tissue.
Ciprofloxacin exhibits a broad spectrum of antibacterial activity which includes all of the common species implicated in prostatitis. We therefore investigated the penetration of this agent into the prostatic tissue of patients undergoing elective suprapubic prostatectomy.
MATERIALS AND METHODS
Patients. Fifteen patients scheduled for routine suprapubic prostatectomy were studied. None of the patients had received antimicrobial agents in the preceding 72 Detroit, Mich.) and Iso-Sensitest agar (pH 7.1 to 7.2; Oxoid Ltd., London, England) and seeded with a clinical isolate of Enterobacter cloacae. The latter had previously been found susceptible to ciprofloxacin (MIC, 0.015 to 0.030 jig/ml).
Standards for serum and tissue assay were prepared in pooled human serum; standards for urine assay were diluted in phosphate buffer (pH 6.2). Standard curves for serum, urine, and tissue assays were prepared in quadruplicate, each with five antibiotic concentrations ranging from 0.037 to 3.0 jig/ml. In each instance, control curves were identical and exhibited coefficients of variation of c3.0% at minimal and maximal concentrations. All plates were examined after overnight incubation at 36°C.
RESULTS
Maximum concentrations of ciprofloxacin in serum ranged from 3.0 to 6.8 ,ug/ml (mean, 4.86 + 0.34 j,g/ml) and were generally observed 2 h after administration ( ciprofloxacin levels measured in urine by bioassay exceed those obtained with high-pressure liquid chromatography (7), whereas a subsequent study found no such difference when urine was analyzed by the two methods (2) . Such discrepancies may be unimportant in the clinical setting, because levels by either method are manyfold those necessary for sterilization of urine. In this regard, bioassay appears to be a more relevant indicator of antimicrobial activity. Ciprofloxacin is active against a variety of gram-positive and gram-negative bacteria which are likely to be encountered in the prostate (3). The spectrum of ciprofloxacin includes additional genitourinary pathogens such as Mycoplasma and Chlamydia organisms, which are generally resistant to many of the antimicrobial agents used for urinary tract infection (9) . Prostatic tissue concentrations detected in most of our samples were in excess of the MIC for susceptible members of the family Enterobacteriaceae, Pseudomonas spp. (0.005 to 0.8 p,g/ml) (3) , and Chlamydia and Mycoplasma spp. (1 to 2 pLg/ml) (9) .
The high and prolonged serum activity observed in our study confirmed previous reports (4) . Penetration of the drug into prostatic tissue and fluid was reported by others after both oral and intravenous administration (1, 5, 6 ; J. B. Boerema, F. M. Debruyne, and A. Dalhoff, Letter, Lancet ii: [695] [696] 1984) . No prior study has appeared in the U.S. literature, and only one investigation was concerned with levels in prostatic tissue after oral administration (1). The latter was limited to assay of tissue <6 h after a single dose of 500 mg. We demonstrated therapeutic tissue concentrations as long as 9 h after administration of 750 mg.
Our data suggest that ciprofloxacin is a valuable agent for the treatment of bacterial prostatitis and related infections of the urinary tract. 
